ProPhase Labs (NASDAQ:PRPH) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of ProPhase Labs (NASDAQ:PRPHGet Rating) in a report released on Tuesday. The firm set a “sell” rating on the stock.

PRPH has been the subject of a number of other research reports. HC Wainwright raised their target price on ProPhase Labs from $15.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, March 31st. TheStreet raised ProPhase Labs from a “d+” rating to a “c-” rating in a research note on Monday, March 28th. Finally, Zacks Investment Research raised ProPhase Labs from a “hold” rating to a “buy” rating and set a $7.75 price target for the company in a research note on Tuesday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, ProPhase Labs currently has an average rating of “Hold” and a consensus target price of $11.88.

ProPhase Labs stock opened at $8.25 on Tuesday. ProPhase Labs has a one year low of $4.41 and a one year high of $8.58. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.65 and a current ratio of 3.95. The business has a fifty day moving average of $7.08 and a two-hundred day moving average of $6.72. The company has a market cap of $127.76 million, a P/E ratio of 21.15 and a beta of 0.01.

Institutional investors have recently added to or reduced their stakes in the stock. Morgan Stanley increased its stake in ProPhase Labs by 354.6% in the first quarter. Morgan Stanley now owns 10,592 shares of the company’s stock valued at $78,000 after purchasing an additional 8,262 shares during the last quarter. HighVista Strategies LLC acquired a new stake in ProPhase Labs during the third quarter worth about $105,000. Marshall Wace LLP acquired a new stake in ProPhase Labs during the third quarter worth about $119,000. Bank of America Corp DE acquired a new stake in ProPhase Labs during the second quarter worth about $177,000. Finally, BlackRock Inc. increased its stake in ProPhase Labs by 14.5% during the third quarter. BlackRock Inc. now owns 28,778 shares of the company’s stock worth $150,000 after acquiring an additional 3,647 shares during the last quarter. Hedge funds and other institutional investors own 10.64% of the company’s stock.

About ProPhase Labs (Get Rating)

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

Featured Articles

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.